120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
基于纳米材料的缺血性卒中药物递送系统：从跨越血脑屏障到神经保护
Authors He Y, Qu M, Yu L, Lu Y, Hong J, Sun M, Yang H, Mi W , Guo H, Ma Y
Received 12 December 2025
Accepted for publication 3 February 2026
Published 11 February 2026 Volume 2026:21 588499
DOI https://doi.org/10.2147/IJN.S588499
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Eng San Thian
Yanan He,1,* Mengyao Qu,1,* Lu Yu,1,* Yiuxn Lu,1 Jin Hong,1 Miao Sun,1 Huikai Yang,1 Weidong Mi,1 Hang Guo,2 Yulong Ma1
1Department of Anesthesiology, the First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China; 2Department of Anesthesiology, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, 100700, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yulong Ma, Email yulongma123@163.com Weidong Mi, Email wwdd1962@163.com
Abstract: Ischemic stroke remains a leading cause of mortality and long-term disability worldwide, largely due to limited therapeutic options and the restrictive nature of the blood–brain barrier (BBB). Nanomaterial-based drug delivery systems have emerged as promising strategies to enhance brain-targeted therapy by facilitating BBB penetration and enabling multi-pathway neuroprotection. This review provides a mechanism-driven overview of recent advances in stroke nanomedicine, classifying nanotherapeutic strategies into four major categories: reactive oxygen species–scavenging nanomaterials, glutamate-modulating systems, anti-inflammatory nanocarriers, and neuroprotective or neuroregenerative delivery platforms. Representative nanoplatforms within each category are discussed with respect to their BBB-crossing mechanisms, therapeutic potential, and translational relevance. In addition, the current clinical trial landscape, key translational bottlenecks, and emerging artificial intelligence–assisted approaches for optimizing nanocarrier design and supporting translational decision-making are highlighted. Overall, this review aims to provide a structured, clinically oriented framework to guide the rational design and translational development of nanomaterial-based drug delivery systems for ischemic stroke.
Keywords: ischemic stroke, nanomedicine, blood-brain barrier, neuroprotection, drug delivery
1Department of Anesthesiology, the First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China; 2Department of Anesthesiology, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, 100700, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yulong Ma, Email yulongma123@163.com Weidong Mi, Email wwdd1962@163.com
Abstract: Ischemic stroke remains a leading cause of mortality and long-term disability worldwide, largely due to limited therapeutic options and the restrictive nature of the blood–brain barrier (BBB). Nanomaterial-based drug delivery systems have emerged as promising strategies to enhance brain-targeted therapy by facilitating BBB penetration and enabling multi-pathway neuroprotection. This review provides a mechanism-driven overview of recent advances in stroke nanomedicine, classifying nanotherapeutic strategies into four major categories: reactive oxygen species–scavenging nanomaterials, glutamate-modulating systems, anti-inflammatory nanocarriers, and neuroprotective or neuroregenerative delivery platforms. Representative nanoplatforms within each category are discussed with respect to their BBB-crossing mechanisms, therapeutic potential, and translational relevance. In addition, the current clinical trial landscape, key translational bottlenecks, and emerging artificial intelligence–assisted approaches for optimizing nanocarrier design and supporting translational decision-making are highlighted. Overall, this review aims to provide a structured, clinically oriented framework to guide the rational design and translational development of nanomaterial-based drug delivery systems for ischemic stroke.
Keywords: ischemic stroke, nanomedicine, blood-brain barrier, neuroprotection, drug delivery